SPRY has been successfully added to your Stock Email Alerts list.
You can manage your stock email alerts here.
SPRY has been removed from your Stock Email Alerts list.
Please enter Portfolio Name for new portfolio.
The PE Ratio (TTM), or Price-to-Earnings ratio, or P/E Ratio, is a financial ratio used to compare a company's market price to its Earnings per Share (Diluted). As of today (2024-12-13), ARS Pharmaceuticals's share price is $12.64. ARS Pharmaceuticals's Earnings per Share (Diluted) for the trailing twelve months (TTM) ended in Sep. 2024 was $-0.51. Therefore, ARS Pharmaceuticals's PE Ratio (TTM) for today is At Loss.
The historical rank and industry rank for ARS Pharmaceuticals's PE Ratio (TTM) or its related term are showing as below:
ARS Pharmaceuticals's Earnings per Share (Diluted) for the three months ended in Sep. 2024 was $-0.20. Its Earnings per Share (Diluted) for the trailing twelve months (TTM) ended in Sep. 2024 was $-0.51.
As of today (2024-12-13), ARS Pharmaceuticals's share price is $12.64. ARS Pharmaceuticals's EPS without NRI for the trailing twelve months (TTM) ended in Sep. 2024 was $-0.51. Therefore, ARS Pharmaceuticals's PE Ratio without NRI for today is At Loss.
ARS Pharmaceuticals's EPS without NRI for the three months ended in Sep. 2024 was $-0.20. Its EPS without NRI for the trailing twelve months (TTM) ended in Sep. 2024 was $-0.51.
During the past 3 years, the average EPS without NRI Growth Rate was -272.80% per year.
During the past 4 years, ARS Pharmaceuticals's highest 3-Year average EPS without NRI Growth Rate was -272.80% per year. The lowest was -272.80% per year. And the median was -272.80% per year.
ARS Pharmaceuticals's EPS (Basic) for the three months ended in Sep. 2024 was $-0.20. Its EPS (Basic) for the trailing twelve months (TTM) ended in Sep. 2024 was $-0.51.
The historical data trend for ARS Pharmaceuticals's PE Ratio (TTM) can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
ARS Pharmaceuticals Annual Data | |||||||||
Trend | Dec20 | Dec21 | Dec22 | Dec23 | |||||
PE Ratio (TTM) | N/A | N/A | At Loss | At Loss |
ARS Pharmaceuticals Quarterly Data | ||||||||||||||
Dec20 | Jun21 | Dec21 | Mar22 | Jun22 | Sep22 | Dec22 | Mar23 | Jun23 | Sep23 | Dec23 | Mar24 | Jun24 | Sep24 | |
PE Ratio (TTM) | Get a 7-Day Free Trial | At Loss | At Loss | At Loss | At Loss | At Loss |
For the Biotechnology subindustry, ARS Pharmaceuticals's PE Ratio (TTM), along with its competitors' market caps and PE Ratio (TTM) data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
For the Biotechnology industry and Healthcare sector, ARS Pharmaceuticals's PE Ratio (TTM) distribution charts can be found below:
* The bar in red indicates where ARS Pharmaceuticals's PE Ratio (TTM) falls into.
The PE Ratio (TTM), or Price-to-Earnings ratio, or P/E Ratio, is a financial ratio used to compare a company's market price to its Earnings per Share (Diluted). It is the most widely used ratio in the valuation of stocks.
ARS Pharmaceuticals's PE Ratio (TTM) for today is calculated as
PE Ratio (TTM) | = | Share Price | / | Earnings per Share (Diluted) (TTM) |
= | 12.64 | / | -0.510 | |
= | At Loss |
ARS Pharmaceuticals's Share Price of today is $12.64.
ARS Pharmaceuticals's Earnings per Share (Diluted) for the trailing twelve months (TTM) ended in Sep. 2024 adds up the quarterly data reported by the company within the most recent 12 months, which was $-0.51.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
It can also be calculated from the numbers for the whole company:
PE Ratio (TTM) | = | Market Cap | / | Net Income |
There are at least three kinds of PE Ratio (TTM)s used by different investors. They are Trailing Twelve Month PE Ratio (TTM) or PE Ratio (TTM) (TTM), Forward PE Ratio, or PE Ratio without NRI. A new PE Ratio (TTM) based on inflation-adjusted normalized PE Ratio (TTM) is called Shiller PE Ratio, after Yale professor Robert Shiller.
In the calculation of PE Ratio (TTM), the earnings per share used are the earnings per share over the past 12 months. For Forward PE Ratio, the earnings are the expected earnings for the next twelve months. In the case of PE Ratio without NRI, the reported earnings less the non-recurring items are used.
For Shiller PE Ratio, the earnings of the past 10 years are inflation-adjusted and averaged. Since it looks at the average over the last 10 years, Shiller PE Ratio is also called PE10.
ARS Pharmaceuticals (NAS:SPRY) PE Ratio (TTM) Explanation
The PE Ratio (TTM) can be viewed as the number of years it takes for the company to earn back the price you pay for the stock. For example, if a company earns $2 a share per year, and the stock is traded at $30, the PE Ratio (TTM) is 15. Therefore it takes 15 years for the company to earn back the $30 you paid for its stock, assuming the earnings stays constant over the next 15 years.
In real business, earnings never stay constant. If a company can grow its earnings, it takes fewer years for the company to earn back the price you pay for the stock. If a company's earnings decline it takes more years. As a shareholder, you want the company to earn back the price you pay as soon as possible. Therefore, lower P/E stocks are more attractive than higher P/E stocks so long as the PE Ratio (TTM) is positive. Also for stocks with the same PE Ratio (TTM), the one with faster growth business is more attractive.
If a company loses money, the PE Ratio (TTM) becomes meaningless.
To compare stocks with different growth rates, Peter Lynch invented a ratio called PEG Ratio. PEG Ratio is defined as the PE Ratio (TTM) divided by the growth ratio. He thinks a company with a PE Ratio (TTM) equal to its growth rate is fairly valued. Still he said he would rather buy a company growing 20% a year with a PE Ratio (TTM) of 20, instead of a company growing 10% a year with a PE Ratio (TTM) of 10.
Because the PE Ratio (TTM) measures how long it takes to earn back the price you pay, the PE Ratio (TTM) can be applied to the stocks across different industries. That is why it is the one of the most important and widely used indicators for the valuation of stocks.
Similar to the PE Ratio without NRI or PS Ratio or Price-to-Operating-Cash-Flow or Price-to-Free-Cash-Flow , the PE Ratio (TTM) measures the valuation based on the earning power of the company. This is where it is different from the PB Ratio , which measures the valuation based on the company's balance sheet.
Be Aware
Investors need to be aware that the PE Ratio (TTM) can be misleading a lot of times, especially when the underlying business is cyclical and unpredictable. As Peter Lynch pointed out, cyclical businesses have higher profit margins at the peaks of the business cycles. Their earnings are high and PE Ratio (TTM)s are artificially low. It is usually a bad idea to buy a cyclical business when the PE Ratio (TTM) is low. A better ratio to identify the time to buy a cyclical businesses is the PS Ratio .
PE Ratio (TTM) can also be affected by non-recurring-items such as the sale of part of businesses. This may increase for the current year or quarter dramatically. But it cannot be repeated over and over. Therefore PE Ratio without NRI is a more accurate indication of valuation than PE Ratio (TTM).
Thank you for viewing the detailed overview of ARS Pharmaceuticals's PE Ratio (TTM) provided by GuruFocus.com. Please click on the following links to see related term pages.
Laura Shawver | director, officer: Chief Executive Officer | 1255 CRESCENT GREEN DRIVE, SUITE 250, CARY NC 27518 |
Eric Karas | officer: Chief Commercial Officer | C/O ARS PHARMACEUTICALS, INC., 11682 EL CAMINO REAL, SUITE 120, SAN DIEGO CA 92130 |
Justin Chakma | officer: Chief Business Officer | C/O ARS PHARMACEUTICALS, INC., 11682 EL CAMINO REAL, SUITE 120, SAN DIEGO CA 92130 |
Richard E Lowenthal | director, 10 percent owner, officer: President and CEO | 12481 HIGH BLUFF DRIVE, SUITE 200, SAN DIEGO CA 92130 |
Sarina Tanimoto | 10 percent owner, officer: Chief Medical Officer | C/O ARS PHARMACEUTICALS, INC., 11682 EL CAMINO REAL, SUITE 120, SAN DIEGO CA 92130 |
James E Flynn | director, 10 percent owner, other: Director by deputization | 780 THIRD AVENUE, 37TH FLOOR, NEW YORK NY 10017 |
Kathleen D. Scott | officer: Chief Financial Officer | C/O CONATUS PHARMACEUTICALS INC., 16745 WEST BERNARDO DRIVE, SUITE 200, SAN DIEGO CA 92127 |
Orbimed Advisors Llc | director | 601 LEXINGTON AVENUE, 54TH FLOOR, NEW YORK NY 10022 |
Peter A. Thompson | director | C/O ANTHERA PHARMACEUTICALS, INC., 25801 INDUSTRIAL BOULEVARD, SUITE B, HAYWARD CA 94545 |
Brian Dorsey | officer: Chief Operating Officer | C/O SOMAXON PHARMACEUTICALS, INC., 10935 VISTA SORRENTO PARKWAY, SUITE 250, SAN DIEGO CA 92130 |
Ra Capital Healthcare Fund Lp | director | 200 BERKELEY STREET, 18TH FLOOR, BOSTON MA 02116 |
Alexander A Fitzpatrick | officer: Chief Legal Officer | 9605 SCRANTON ROAD, SUITE 200, SAN DIEGO CA 92121 |
Orbimed Capital Gp Vi Llc | director | 601 LEXINGTON AVENUE, 54TH FLOOR, NEW YORK NY 10022 |
Rajeev Dadoo | director | C/O ARS PHARMACEUTICALS, INC., 11682 EL CAMINO REAL, SUITE 120, SAN DIEGO CA 92130 |
Pratik Shah | director, 10 percent owner | 3366 N. TORREY PINES COURT, SUITE 220, LA JOLLA CA 92037 |
From GuruFocus
By Marketwired • 09-10-2024
By Marketwired • 08-09-2024
By GuruFocus Research • 02-09-2024
By GuruFocus Research • 03-21-2024
By Marketwired • 08-06-2024
By Marketwired • 09-04-2024
By Marketwired • 12-04-2024
By GuruFocus News • 12-05-2024
By GuruFocus News • 11-14-2024
By Marketwired • 08-07-2024
Disclaimers: GuruFocus.com is not operated by a broker or a dealer. It has an affiliated registered investment adviser, which serves as the subadviser to an exchange traded fund. This investment adviser does not provide advice to individual investors. Under no circumstances does any information posted on GuruFocus.com represent a recommendation to buy or sell a security. The information on this site, and in its related newsletters, is not intended to be, nor does it constitute investment advice or recommendations. The individuals or entities selected as "gurus" may buy and sell securities before and after any particular article and report and information herein is published, with respect to the securities discussed in any article and report posted herein. Gurus may be added or dropped from the GuruFocus site at any time. In no event shall GuruFocus.com be liable to any member, guest or third party for any damages of any kind arising out of the use of any content or other material published or available on GuruFocus.com, or relating to the use of, or inability to use, GuruFocus.com or any content, including, without limitation, any investment losses, lost profits, lost opportunity, special, incidental, indirect, consequential or punitive damages. Past performance is a poor indicator of future performance. The information on this site, and in its related newsletters, is not intended to be, nor does it constitute investment advice or recommendations. The information on this site is in no way guaranteed for completeness, accuracy or in any other way. The gurus listed in this website are not affiliated with GuruFocus.com, LLC. Stock quotes provided by InterActive Data. Fundamental company data provided by Morningstar, updated daily.